RLFTF (Relief Therapeutics Holding) FCF Margin %: -309.68% (As of Jun. 2025)


RLFTF Relief Therapeutics Holding SA RLFTF
31 GF Score
Price $0.29
GF Value $0.61
! 5 Warning Signs
View Full Analysis

What is Relief Therapeutics Holding FCF Margin %?

Relief Therapeutics Holding RLFTF +0.56% 31 FCF Margin % is -309.68% as of Jun. 2025. GuruFocus rates RLFTF with a GF Score™ of 31/100 and a GF Value™ of $0.61. The stock has 5 warning signs investors should review.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Relief Therapeutics Holding's Free Cash Flow for the six months ended in Jun. 2025 was $-4.64 Mil. Relief Therapeutics Holding's Revenue for the six months ended in Jun. 2025 was $1.50 Mil. Therefore, Relief Therapeutics Holding's FCF Margin % for the quarter that ended in Jun. 2025 was -309.68%.

As of today, Relief Therapeutics Holding's current FCF Yield % is -124.06%.

The historical rank and industry rank for Relief Therapeutics Holding's FCF Margin % or its related term are showing as below:

RLFTF' s FCF Margin % Range Over the Past 10 Years
Min: -19326.67   Med: -352.32   Max: -36.69
Current: -95.21

During the past 13 years, the highest FCF Margin % of Relief Therapeutics Holding was -36.69%. The lowest was -19326.67%. And the median was -352.32%.

RLFTF's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -84.65 vs RLFTF: -95.21

Relief Therapeutics Holding FCF Margin % Related Terms

Relief Therapeutics Holding FCF Margin % Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding FCF Margin % Chart

Relief Therapeutics Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1,488.24 -405.33 -299.33 -36.69

Relief Therapeutics Holding Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -358.47 -239.93 -58.26 5.78 -309.68

RLFTF vs KTTA, OSRH, LIMN: FCF Margin % Comparison

For the Biotechnology subindustry, Relief Therapeutics Holding's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relief Therapeutics Holding FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's FCF Margin % falls into.


RLFTF
31GF Score
Relief Therapeutics Holding SA RLFTF
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relief Therapeutics Holding FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Relief Therapeutics Holding's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-3.464/9.44
=-36.69 %

Relief Therapeutics Holding's FCF Margin for the quarter that ended in Jun. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-4.639/1.498
=-309.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -309.68% mean?
Relief Therapeutics Holding (RLFTF) has a FCF Margin % of -309.68% as of Jun. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's FCF Margin % too high?
Relief Therapeutics Holding's current FCF Margin % is -309.68%. Overall, Relief Therapeutics Holding has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's FCF Margin % compare to KTTA and OSRH?
Relief Therapeutics Holding's FCF Margin % of -309.68% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current FCF Margin % is -309.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (RLFTF) has a current FCF Margin % of -309.68%. The stock's GF Value™ is $0.61, compared to a current price of $0.29 — trading 53.3% below its estimated fair value. The current FCF Margin % is -309.68%. Relief Therapeutics Holding's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Relief Therapeutics Holding (RLFTF), the current FCF Margin % is -309.68% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (RLFTF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of $0.29 is trading 53.3% below its estimated GF Value™ of $0.61.

Key valuation signals for RLFTF:

  • FCF Margin %: -309.68%
  • GF Value™: $0.61 vs. price of $0.29 (53.3% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the RLFTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relief Therapeutics Holding Business Description

Address Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
31GF Score

Get the complete analysis for RLFTF

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price
$0.61
GF Value